Nakamura, Yoshihiro
Inaguma, Daijo
Imaizumi, Takahiro
Kurasawa, Shimon
Hishida, Manabu
Okazaki, Masaki
Fujishima, Yuki
Nishibori, Nobuhiro
Suzuki, Katsuhiko
Takeda, Yuki
Maruyama, Shoichi
Article History
Received: 13 October 2023
Revised: 9 January 2024
Accepted: 27 January 2024
First Online: 4 March 2024
Compliance with ethical standards
:
: D.I. has received research funding from The Aichi Kidney Foundation. T.I. has received grants and honoraria from Kyowa Kirin; consulting fees from GlaxoSmithKline. S.M. has received grants and/or research funding from Chugai, Mitsubishi Tanabe, Ono, and ROHTO; honoraria from Alexion, Astellas, AstraZeneca, Bayer, Mitsubishi Tanabe, Kyowa Kirin, and Novartis.
: This study was approved by the Institutional Review Board of Nagoya Daini Red Cross Hospital and each participating facility in the AICOPP group (the approval number: 20110823-3) and was conducted in accordance with the Ethical guidelines for Clinical Research by the Japanese Ministry of Health, Labor, and Welfare (created July 30, 2003; full revision December 28, 2004; full revision July 31, 2008) and the Helsinki Declaration (revised 2013). The subjects received oral and written explanations of the purpose of the study and provided their written consent.